Phase-III-Trial with biosimilar

Formycon and bioeq initiate pivotal Phase III clinical trial with FYB201,
an investigational biosimilar ranibizumab (Lucentis®)

Learn More

Mid-Year Report

In the first half of 2015, Formycon continued moving rapidly forward on its path of success.


Third product
for the third wave

Formycon AG commences development
of its third product.

Learn more

21st Century

What makes Formycon unique.

Learn more


8th Biosimilars Congregation

Lecture by Carsten Brockmeyer, PhD
Date: March 8 – 9, 2016
Location: London, UK

Financial reports, 2014

Annual report 2014

Published on May 19, 2015

Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon’s specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has three biosimilars under development, with further product candidates already identified. Two biosimilar candidates have been licensed out to Santo Holding GmbH.